MetLife Investment Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

MetLife Investment Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-688	Closed	-$156K	–	2851
2022 Q3	$156K	Buy	688 +210	+44%	+$51.6K	﹤0.01%	2447
2022 Q2	$90.3K	Sell	478 -184	-28%	-$37.1K	﹤0.01%	2743
2022 Q1	$165K	Buy	+662	New	+$105K	﹤0.01%	2469
2021 Q1	–	Sell	-402	Closed	-$148K	–	2338
2020 Q4	$148K	Hold	402	–	–	﹤0.01%	2131
2020 Q3	$98.3K	Hold	402	–	–	﹤0.01%	2217
2020 Q2	$116K	Buy	+402	New	+$118K	﹤0.01%	2186
2020 Q1	–	Sell	-421	Closed	-$188K	–	2308
2019 Q4	$188K	Hold	421	–	–	﹤0.01%	2009
2019 Q3	$129K	Hold	421	–	–	﹤0.01%	2190
2019 Q2	$134K	Buy	+421	New	+$146K	﹤0.01%	2244

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MetLife Investment Management's EIGR Position: Q4 2022 in Review

MetLife Investment Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 688 shares — an estimated $156K sold.

MetLife Investment Management first reported a position in EIGR in Q2 2019 and held it in 9 quarters. The position peaked at $188K in Q4 2019. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

MetLife Investment Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
MetLife Investment Management sold 688 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $156K.
MetLife Investment Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 9 quarters.
MetLife Investment Management's Eiger BioPharmaceuticals, Inc. position peaked at $188K in Q4 2019.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on MetLife Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.